Top in endocrinology: Midlife migraine, weight loss goals in diabetes
Research presented at the North American Menopause Society annual meeting suggests that hormones play a role in midlife migraine attacks among women.
During a presentation, Carolyn Bernstein, MD, FAHS, discussed potential treatment strategies for these migraine attacks. It was the top story in endocrinology last week.
Meanwhile, at the European Association for the Study of Diabetes annual meeting, a speaker said that losing 15% of body weight should be a top treatment goal for most patients with type 2 diabetes. A summary of the presentation was another top story.
Read these and more news in endocrinology below:
Midlife migraines ‘treatable,’ but team-based approach needed
The cause of midlife migraines in women is likely multifactorial, though research suggests that fluctuating hormone levels may play a role, according to a speaker at the North American Menopause Society annual meeting. Read more.
Weight loss of 15% should be primary goal for most people with type 2 diabetes
Losing 15% of body weight should be a primary treatment goal for most people with type 2 diabetes and could help lead to diabetes remission, according to speakers. Read more.
Mortality after bariatric surgery ‘remarkably worse’ for men than women
A significantly higher mortality rate was observed for men compared with women, both short term and long term, after bariatric surgery, according to a speaker at the European Association for the Study of Diabetes virtual meeting. Read more.
Medtronic expands recall of insulin pump controllers due to cybersecurity risks
Medtronic expanded a recall of remote controllers used with MiniMed 508 insulin pump or the MiniMed Paradigm family of insulin pumps due to potential cybersecurity risks, according to an FDA press release. Read more.
Finerenone plus SGLT2 inhibition may yield additive CV, kidney benefits: FIGARO-DKD
The nonsteroidal mineralocorticoid receptor antagonist finerenone provides cardiovascular and kidney benefits in adults with diabetic kidney disease independent of and combined with SGLT2 inhibitors, new analyses show. Read more.